(63 days)
Not Found
No
The description focuses on automated quantitative or qualitative susceptibility testing using a miniaturized doubling dilution technique and monitoring growth over time. There is no mention of AI or ML algorithms being used for analysis or interpretation.
No.
This device is a diagnostic tool used for antimicrobial susceptibility testing, providing information on how effective certain antibiotics are against specific bacterial strains. It does not directly treat or provide therapy to a patient.
Yes
The device is designed for "antimicrobial susceptibility testing of Streptococcus species" and is a "qualitative test intended for use... as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents." This directly contributes to diagnosing the susceptibility of bacteria to certain treatments, which is a diagnostic function.
No
The device description explicitly details physical components (VITEK® 2 AST Cards) and hardware systems (VITEK® 2 and VITEK® 2 Compact Systems) used for testing. It is not solely software.
Based on the provided text, the device is indeed an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The text explicitly states the device is "designed for antimicrobial susceptibility testing of Streptococcus species" and is a "qualitative test intended for use with the VITEK® 2 and VITEK® 2 Compact Systems as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents." "In vitro" means "in glass" or "in the laboratory," which is a key characteristic of IVDs.
- Device Description: The description details how the device uses bacterial isolates and antimicrobial agents in a laboratory setting to determine susceptibility.
- Performance Studies: The performance studies compare the device's performance to a "CLSI broth microdilution reference method," which is a standard laboratory technique for determining antimicrobial susceptibility.
- Intended User: The intended user is described as a "laboratory aid," further indicating its use in a clinical laboratory setting.
All these points align with the definition and purpose of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
VITEK® 2 Streptococcus Clindamycin is designed for antimicrobial susceptibility testing of Streptococcus species. VITEK® 2 Streptococcus Clindamycin is a qualitative test intended for use with the VITEK® 2 and VITEK® 2 Compact Systems as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents. Clindamycin has been shown to be active in vitro against most strains of the microorganisms listed below, as described in the FDA-approved package insert for this antimicrobial agent.
Active in vitro and in clinical infections against:
Streptococcus pneumoniae (penicillin-susceptible strains) Streptococcus pyogenes
Active in vitro against:
Streptococcus agalactiae Streptococcus anginosus Streptococcus mitis Streptococcus oralis
The VITEK 2 Antimicrobial Susceptibility Test (AST) is intended to be used with the VITEK® 2 System for the automated quantitative or qualitative susceptibility testing of isolated colonies for the most clinically significant aerobic gram-negative bacilli, Staphylococcus spp., Enterococcus spp., Streptococcus spp. and clinically significant yeast.
Product codes (comma separated list FDA assigned to the subject device)
LON
Device Description
VITEK® 2 Streptococcus Clindamycin is designed for antimicrobial susceptibility testing of Streptococcus species. VITEK 2 Streptococcus Clindamycin is a qualitative test intended for use with the VITEK® 2 and VITEK® 2 Compact Systems as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents. Clindamycin has been shown to be active in vitro against most strains of the microorganisms listed below, as described in the FDA-approved package insert for this antimicrobial agent.
The antimicrobial agent presented in the VITEK® 2 AST Cards is in concentrations equivalent by efficacy to standard method concentrations in mcg/ml. The VITEK® 2 AST Cards are essentially miniaturized versions of the doubling dilution technique for determining the minimum inhibitory concentration (MIC) microdilution methodology.
The bacterial isolate to be tested is diluted to a standardized concentration in 0.45 - 0.50% saline before being used to rehydrate the antimicrobial medium within the card. The VITEK® 2 System automatically fills, seals and places the card into the incubator/reader. The VITEK® 2 Compact has a manual filling and sealing operation. The VITEK® 2 monitors the growth of each well in the card over a defined period of time (up to 36 hours for yeast). At the completion cycle, a report is generated that contains the MIC value along with the interpretive category result for each antibiotic contained on the card.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
laboratory aid
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
An external evaluation was conducted with fresh and stock clinical isolates, as well as a set of challenge strains. The external evaluations were designed to confirm the acceptability of VITEK® 2 Streptococus Clindamycin by comparing its performance with the CLSI broth microdilution reference method. The data is representative of performance on both the VITEK® 2 and VITEK® 2 Compact instrument platforms.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
VITEK 2 Streptoccocus Clindamycin demonstrated substantially equivalent performance when compared with the CLSI broth microdilution reference method, as defined in the FDA Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA. Issued August. 28, 2009.
VITEK 2 Streptococus Clindamycin demonstrated acceptable performance of 97.2% overall category agreement with the reference method. Reproducibility and Quality Control demonstrated acceptable results using both the VITEK 2 Compact instrument systems.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
97.2% overall category agreement
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 866.1645 Fully automated short-term incubation cycle antimicrobial susceptibility system.
(a)
Identification. A fully automated short-term incubation cycle antimicrobial susceptibility system is a device that incorporates concentrations of antimicrobial agents into a system for the purpose of determining in vitro susceptibility of bacterial pathogens isolated from clinical specimens. Test results obtained from short-term (less than 16 hours) incubation are used to determine the antimicrobial agent of choice to treat bacterial diseases.(b)
Classification. Class II (special controls). The special control for this device is FDA's guidance document entitled “Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA.”
0
K 11/2129
Image /page/0/Picture/1 description: The image shows the logo for BIOMÉRIEUX. The logo features the company name in a stylized font below a circular graphic. The circle is divided into two halves, with one half containing horizontal lines and the other half being solid black. A curved line extends from the top of the circle down past the company name.
SEP 2 7 2011
510(k) SUMMARY
VITEK® 2 Streptococcus Clindamycin
510(k) Submission Information:
| Submitter's Name: | bioMérieux, Inc. |
|---|---|
| Address: | 595 Anglum Road |
| Hazelwood, MO 63042 | |
| Contact Person: | Jolyn Tenllado |
| Director, Regulatory Affairs | |
| Phone Number: | 314-731-8386 |
| Fax Number: | 314-731-8689 |
| Date of Preparation: | July 25, 2011 |
B. Device Name:
| Formal/Trade Name: | VITEK® 2 Streptococcus Clindamycin |
|---|---|
| Classification Name: | Fully Automated Short-Term Incubation Cycle Antimicrobial Susceptibility Device, 21 CFR 866.1645 Product Code LON |
| Common Name: | VITEK® 2 AST-ST Clindamycin |
| Predicate Device: | VITEK® 2 Gram Positive Amoxicillin for Streptococcus |
pneumoniae (K063597)
D. 510(k) Summary:
C.
VITEK® 2 Streptococcus Clindamycin is designed for antimicrobial susceptibility testing of Streptococcus species. VITEK 2 Streptococcus Clindamycin is a qualitative test intended for use with the VITEK® 2 and VITEK® 2 Compact Systems as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents. Clindamycin has been shown to be active in vitro against most strains of the microorganisms listed below, as described in the FDA-approved package insert for this antimicrobial agent.
Active in vitro and in clinical infections against:
Streptococcus pneumoniae (penicillin-susceptible strains) Streptococcus pyogenes
Active in vitro against:
Streptococcus agalactiae Streptococcus anqinosus Streptococcus mitis Streptococcus oralis
1
The antimicrobial agent presented in the VITEK® 2 AST Cards is in concentrations equivalent by efficacy to standard method concentrations in mcg/ml. The VITEK® 2 AST Cards are essentially miniaturized versions of the doubling dilution technique for determining the minimum inhibitory concentration (MIC) microdilution methodology.
The bacterial isolate to be tested is diluted to a standardized concentration in 0.45 - 0.50% saline before being used to rehydrate the antimicrobial medium within the card. The VITEK® 2 System automatically fills, seals and places the card into the incubatorfreader. The VITEK® 2 Compact has a manual filling and sealing operation. The VITEK® 2 monitors the growth of each well in the card over a defined period of time (up to 36 hours for yeast). At the completion cycle, a report is generated that contains the MIC value along with the interpretive category result for each antibiotic contained on the card.
VITEK 2 Streptoccocus Clindamycin demonstrated substantially equivalent performance when compared with the CLSI broth microdilution reference method, as defined in the FDA Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA. Issued August. 28, 2009.
The Premarket Notification (510/k)) presents data in support of VITEK® 2 Streptococus Clindamycin. An external evaluation was conducted with fresh and stock clinical isolates, as well as a set of challenge strains. The external evaluations were designed to confirm the acceptability of VITEK® 2 Streptococus Clindamycin by comparing its performance with the CLSI broth microdilution reference method. The data is representative of performance on both the VITEK® 2 and VITEK® 2 Compact instrument platforms. VITEK 2 Streptococus Clindamycin demonstrated acceptable performance of 97.2% overall category agreement with the reference method. Reproducibility and Quality Control demonstrated acceptable results using both the VITEK 2 Compact instrument systems.
2
Image /page/2/Picture/1 description: The image shows the seal of the U.S. Department of Health and Human Services. The seal features a stylized eagle with its wings spread, symbolizing protection and service. The eagle is positioned to the right of a circular border containing the words "DEPARTMENT OF HEALTH & HUMAN SERVICES U.S.A.". The seal represents the department's mission to enhance the health and well-being of Americans.
Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993
bioMérieux, Inc. c/o Ms. Jolyn Tenllado Director. Regulatory Affairs 595 Anglum Rd. Hazelvood. Missouri 63042
SEP 27 2011
Re: K112129
Trade/Device Name: VITEK® 2 Streptococcus Clindamycin (≤0.25- ≥1μg/mL) Regulation Number: 21 CFR§ 866.1645 Regulation Name: Short-Term Antimicrobial Susceptibility Test System Regulatory Class: Class II Product Code: LON Dated: July 25, 2011 Received: July 26, 2011
Dear Ms. Tenllado:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice
3
Page 2 - Jolyn Tenllado
requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/Reportal?roblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Sally A. Hojvat, M.Sc., Ph.D. Director Division of Microbiology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
4
Indications for Use
510(k) Number (if known): K || 2 | 2
VITEK® 2 Streptococcus Clindamycin Device Name: ( ≤ 0.25 - ≥ 1 µg/mL)
Indications For Use:
VITEK® 2 Streptococcus Clindamycin is designed for antimicrobial susceptibility testing of Streptococcus species. VITEK® 2 Streptococcus Clindamycin is a qualitative test intended for use with the VITEK® 2 and VITEK® 2 Compact Systems as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents. Clindamycin has been shown to be active in vitro against most strains of the microorganisms listed below, as described in the FDA-approved package insert for this antimicrobial agent.
Active in vitro and in clinical infections against:
Streptococcus pneumoniae (penicillin-susceptible strains) Streptococcus pyogenes
Active in vitro against:
Streptococcus agalactiae Streptococcus anginosus Streptococcus mitis Streptococcus oralis
The VITEK 2 Antimicrobial Susceptibility Test (AST) is intended to be used with the VITEK® 2 System for the automated quantitative or qualitative susceptibility testing of isolated colonies for the most clinically significant aerobic gram-negative bacilli, Staphylococcus spp., Enterococcus spp., Streptococcus spp. and clinically significant yeast.
Prescription Use × (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)
Freddie Poole
Division Sign Off
Office of In Vitro Diagnostic Device Evaluation and Safety
510(K) K112129